Market Cap
US$13.8b
Last Updated
2019/10/22 23:54 UTC
Data Sources
Company Financials +
Executive Summary
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
Snowflake
Fundamentals
Reasonable growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has DexCom's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-1.4%
DXCM
-1.6%
US Medical Equipment
0.07%
US Market
1 Year Return
15.1%
DXCM
13.8%
US Medical Equipment
8.9%
US Market
Return vs Industry: DXCM matched the US Medical Equipment industry which returned 13.8% over the past year.
Return vs Market: DXCM exceeded the US Market which returned 8.9% over the past year.
Shareholder returns
| DXCM | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.4% | -1.6% | 0.07% |
| 30 Day | -2.3% | -4.3% | -0.3% |
| 90 Day | -1.4% | -4.3% | -1.6% |
| 1 Year | 15.1%15.1% | 14.7%13.8% | 11.3%8.9% |
| 3 Year | 88.1%88.1% | 70.7%65.6% | 46.3%36.8% |
| 5 Year | 241.7%241.7% | 117.3%93.5% | 62.1%44.3% |
Price Volatility Vs. Market
How volatile is DexCom's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Is DexCom, Inc.'s (NASDAQ:DXCM) CEO Overpaid Relative To Its Peers?1 month ago | Simply Wall St
Quentin Blackford Is The Executive VP & CFO of DexCom, Inc. (NASDAQ:DXCM) And They Just Sold 51% Of Their Shares2 months ago | Simply Wall St
Can You Imagine How Chuffed DexCom's (NASDAQ:DXCM) Shareholders Feel About Its 253% Share Price Gain?Valuation
Is DexCom undervalued compared to its fair value and its price relative to the market?
19.99x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: DXCM ($150.89) is trading above our estimate of fair value ($114.02)
Significantly Below Fair Value: DXCM is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DXCM is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: DXCM is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DXCM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DXCM is overvalued based on its PB Ratio (20x) compared to the US Medical Equipment industry average (3.7x).
Next Steps
Future Growth
How is DexCom forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
46.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DXCM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).
Earnings vs Market: DXCM is forecast to become profitable over the next 3 year, which is considered above average market growth.
High Growth Earnings: DXCM's loss is forecast to worsen by 0% next year.
Revenue vs Market: DXCM's revenue (15.3% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: DXCM's revenue (15.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DXCM's Return on Equity is forecast to be low in 3 years time (14.3%).
Next Steps
Past Performance
How has DexCom performed over the past 5 years?
-21.2%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: DXCM is unprofitable, and losses have increased over the past 5 years at a rate of -21.2% per year.
Accelerating Growth: Unable to compare DXCM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DXCM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).
Return on Equity
High ROE: DXCM has a negative Return on Equity (-24.77%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: DXCM is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: DXCM is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is DexCom's financial position?
Financial Position Analysis
Short Term Liabilities: DXCM's short term assets ($1.7B) exceeds its short term liabilities ($288.2M)
Long Term Liabilities: DXCM's short term assets (1.7B) exceeds its long term liabilities (1.1B)
Debt to Equity History and Analysis
Debt Level: DXCM's debt to equity ratio (150.3%) is considered high
Reducing Debt: DXCM's debt to equity ratio has increased from 5.8% to 150.3% over the past 5 years.
Balance Sheet
Inventory Level: DXCM has a low level of unsold assets or inventory.
Debt Coverage by Assets: DXCM's debt is covered by short term assets (assets are 1.685700x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable DXCM has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: DXCM is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 82.9% per year.
Next Steps
Dividend
What is DexCom's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate DXCM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate DXCM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if DXCM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DXCM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DXCM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of DexCom's salary, the management and board of directors tenure and is there insider trading?
3.3yrs
Average management tenure
CEO
Kevin Sayer (61yo)
4.8yrs
Tenure
US$9,554,123
Compensation
Mr. Kevin Ronald Sayer has been Executive Chairman of DexCom, Inc. since July 30, 2018. Mr. Sayer has been the Chief Executive Officer of DexCom, Inc. since January 5, 2015 and as its President since June  ...
CEO Compensation Analysis
Compensation vs. Market: Kevin's total compensation ($USD9.55M) is about average for companies of similar size in the US market ($USD11.18M).
Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
3.3yrs
Average Tenure
49yo
Average Age
Experienced Management: DXCM's management team is considered experienced (3.3 years average tenure).
Board Age and Tenure
5.9yrs
Average Tenure
61yo
Average Age
Experienced Board: DXCM's board of directors are considered experienced (5.9 years average tenure).
Insider Trading
Insider Buying: DXCM insiders have only sold shares in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Senior Key Executive Senior Vice President of Operations |
| Shares | 4,601 |
| Max Price | US$150.11 |
| Entity | Individual |
| Role | Senior Key Executive Executive Vice President of Clinical Affairs |
| Shares | 5,954 |
| Max Price | US$150.11 |
| Entity | Individual |
| Role | Chief Financial Officer Executive VP |
| Shares | 11,686 |
| Max Price | US$150.11 |
| Entity | Individual |
| Role | Head of Human Resources Senior Vice President of Human Resources |
| Shares | 4,600 |
| Max Price | US$150.11 |
| Entity | Individual |
| Shares | 5,843 |
| Max Price | US$150.11 |
| Entity | Individual |
| Role | Chief Technology Officer Executive VP & CTO |
| Shares | 4,712 |
| Max Price | US$150.11 |
| Entity | Individual |
| Role | Head of Corporate Development Executive Vice President of Strategy & Corporate Development |
| Shares | 5,843 |
| Max Price | US$150.11 |
| Entity | Individual |
| Role | Chief Legal Officer Senior VP |
| Shares | 2,495 |
| Max Price | US$150.11 |
| Entity | Individual |
| Role | Senior Key Executive Executive VP & Chief Commercial Officer |
| Shares | 5,843 |
| Max Price | US$150.11 |
| Entity | Individual |
| Role | Chief Executive Officer Executive Chairman |
| Shares | 14,322 |
| Max Price | US$150.11 |
| Entity | Individual |
| Role | Head of Human Resources Senior Vice President of Human Resources |
| Shares | 3,429 |
| Max Price | US$174.59 |
| Entity | Individual |
| Shares | 9,030 |
| Max Price | US$121.08 |
| Entity | Individual |
| Role | Chief Executive Officer Executive Chairman |
| Shares | 26,566 |
| Max Price | US$142.79 |
| Entity | Individual |
| Role | Chief Technology Officer Executive VP & CTO |
| Shares | 8,555 |
| Max Price | US$142.79 |
| Entity | Individual |
| Role | Head of Corporate Development Executive Vice President of Strategy & Corporate Development |
| Shares | 10,811 |
| Max Price | US$142.79 |
| Entity | Individual |
| Role | Chief Legal Officer Senior VP |
| Shares | 3,962 |
| Max Price | US$142.79 |
| Entity | Individual |
| Role | Senior Key Executive Senior Vice President of Operations |
| Shares | 8,531 |
| Max Price | US$142.79 |
| Entity | Individual |
| Role | Senior Key Executive Executive VP & Chief Commercial Officer |
| Shares | 10,811 |
| Max Price | US$142.79 |
| Entity | Individual |
| Role | Head of Human Resources Senior Vice President of Human Resources |
| Shares | 5,793 |
| Max Price | US$142.79 |
| Entity | Individual |
| Shares | 7,653 |
| Max Price | US$142.79 |
| Entity | Individual |
| Role | Chief Financial Officer Executive VP |
| Shares | 5,358 |
| Max Price | US$142.79 |
| Entity | Individual |
| Role | Senior Key Executive Executive Vice President of Clinical Affairs |
| Shares | 10,917 |
| Max Price | US$142.79 |
| Entity | Individual |
| Role | Senior Key Executive Executive VP & Chief Commercial Officer |
| Shares | 1,510 |
| Max Price | US$110.61 |
Ownership Breakdown
Management Team
Kevin Sayer (61yo)
Executive Chairman
- Tenure: 4.8yrs
- Compensation: US$9.55m
Andy Balo (71yo)
Executive Vice President of Clinical Affairs
- Tenure: 11.6yrs
- Compensation: US$3.17m
Steve Pacelli (47yo)
Executive Vice President of Strategy & Corporate Development
- Tenure: 7.2yrs
- Compensation: US$3.17m
Patrick Murphy (40yo)
Senior VP
- Tenure: 2.8yrs
Jeffrey Moy (59yo)
Senior Vice President of Operations
- Tenure: 0.08yrs
Rick Doubleday (56yo)
Executive VP & Chief Commercial Officer
- Tenure: 4.8yrs
- Compensation: US$3.21m
Jake Leach (41yo)
Executive VP & CTO
- Tenure: 1yrs
Quentin Blackford (40yo)
Executive VP
- Tenure: 2.1yrs
- Compensation: US$3.39m
Heather Ace (49yo)
Senior Vice President of Human Resources
- Tenure: 3.3yrs
Sean Christensen
Senior Investor Relations Manager
- Tenure: 0yrs
Board Members
Mark Foletta (58yo)
Lead Independent Director
- Tenure: 3.9yrs
- Compensation: US$373.59k
Steve Altman (58yo)
Independent Director
- Tenure: 5.9yrs
- Compensation: US$318.00k
Kevin Sayer (61yo)
Executive Chairman
- Tenure: 4.8yrs
- Compensation: US$9.55m
Jay Skyler (72yo)
Independent Director
- Tenure: 17.1yrs
- Compensation: US$332.57k
Eric Topol (65yo)
Independent Director
- Tenure: 10.3yrs
- Compensation: US$339.85k
Nick Augustinos (60yo)
Independent Director
- Tenure: 9.9yrs
- Compensation: US$318.00k
Bridgette Heller (58yo)
Director
- Tenure: 0.08yrs
Barbara Kahn (66yo)
Independent Director
- Tenure: 8.5yrs
- Compensation: US$318.00k
Richard Collins (62yo)
Independent Director
- Tenure: 2.6yrs
- Compensation: US$318.00k
Company Information
DexCom, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: DexCom, Inc.
- Ticker: DXCM
- Exchange: NasdaqGS
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$13.759b
- Shares outstanding: 91.19m
- Website: https://www.dexcom.com
Number of Employees
Location
- DexCom, Inc.
- 6340 Sequence Drive
- San Diego
- California
- 92121
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| DXCM | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Apr 2005 |
| DC4 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Apr 2005 |
| DXCM * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Apr 2005 |
Biography
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/22 23:54 |
| End of Day Share Price | 2019/10/22 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.